281 related articles for article (PubMed ID: 34638356)
1. Chemotherapy in Neuroendocrine Tumors.
Das S; Al-Toubah T; Strosberg J
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638356
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
Xu JX; Wu DH; Ying LW; Hu HG
World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.
Das S; Dasari A
Ther Adv Med Oncol; 2021; 13():17588359211018047. PubMed ID: 34093744
[TBL] [Abstract][Full Text] [Related]
4. Current Chemotherapy Use in Neuroendocrine Tumors.
Chan DL; Singh S
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):603-614. PubMed ID: 30098718
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review.
Zappi A; Persano I; Galvani L; Parlagreco E; Andrini E; Campana D; Brizzi MP; Lamberti G; La Salvia A
J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675645
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in NETs: When and how.
Angelousi A; Kaltsas G; Koumarianou A; Weickert MO; Grossman A
Rev Endocr Metab Disord; 2017 Dec; 18(4):485-497. PubMed ID: 28890993
[TBL] [Abstract][Full Text] [Related]
7. Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Marchese U; Gaillard M; Pellat A; Tzedakis S; Abou Ali E; Dohan A; Barat M; Soyer P; Fuks D; Coriat R
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053593
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
9. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors.
Cives M; Pelle' E; Quaresmini D; Mandriani B; Tucci M; Silvestris F
Curr Treat Options Oncol; 2019 Jul; 20(9):72. PubMed ID: 31346813
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
de Mestier L; Lamarca A; Hernando J; Zandee W; Alonso-Gordoa T; Perrier M; Walenkamp AM; Chakrabarty B; Landolfi S; Van Velthuysen MF; Kats-Ugurlu G; Caminoa A; Ronot M; Manoharan P; Garcia-Alvarez A; Brabander T; García Gómez-Muriel MI; Cadiot G; Couvelard A; Capdevila J; Pavel ME; Cros J
Endocr Relat Cancer; 2021 Jun; 28(8):549-561. PubMed ID: 34061764
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
[TBL] [Abstract][Full Text] [Related]
12. Alterations of E-cadherin, alpha-catenin and beta-catenin expression in neuroendocrine tumors of the gastrointestinal tract.
Li CC; Xu B; Hirokawa M; Qian Z; Yoshimoto K; Horiguchi H; Tashiro T; Sano T
Virchows Arch; 2002 Feb; 440(2):145-54. PubMed ID: 11964044
[TBL] [Abstract][Full Text] [Related]
13. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy for Pancreatic Neuroendocrine Tumors.
Wheless M; Das S
Clin Colorectal Cancer; 2023 Mar; 22(1):34-44. PubMed ID: 36114085
[TBL] [Abstract][Full Text] [Related]
15. Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update.
Zhang H; Shen G; Zhang S; Du F; Cao Y; Jiang J; Zheng F; Ma X; Wang Z; Ren D; Ahmad R; Zhao F; Zhao J
Expert Opin Pharmacother; 2018 Jun; 19(8):795-807. PubMed ID: 29693454
[TBL] [Abstract][Full Text] [Related]
16. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
Ooki A; Osumi H; Fukuda K; Yamaguchi K
Cancer Metastasis Rev; 2023 Sep; 42(3):1021-1054. PubMed ID: 37422534
[TBL] [Abstract][Full Text] [Related]
17. Targeting the mTOR signaling pathway in neuroendocrine tumors.
Chan J; Kulke M
Curr Treat Options Oncol; 2014 Sep; 15(3):365-79. PubMed ID: 25092520
[TBL] [Abstract][Full Text] [Related]
18. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Strosberg J; Goldman J; Costa F; Pavel M
Front Horm Res; 2015; 44():239-47. PubMed ID: 26303716
[TBL] [Abstract][Full Text] [Related]
19. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives.
Hirmas N; Jadaan R; Al-Ibraheem A
Nucl Med Mol Imaging; 2018 Jun; 52(3):190-199. PubMed ID: 29942397
[TBL] [Abstract][Full Text] [Related]
20. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
Klimstra DS; Beltran H; Lilenbaum R; Bergsland E
Am Soc Clin Oncol Educ Book; 2015; ():92-103. PubMed ID: 25993147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]